| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6eca83dd237a3986aefdfc1078c3b029 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C317-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C317-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2017-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d60ccf3333812fb3ca4dc6359b735060
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f529c9b2fdb0fdcd9756db0bf56eea4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f49dae5bf2f88dbd138ce8bd6ace395 |
| publicationDate |
2019-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10259786-B2 |
| titleOfInvention |
Psychotropic agents and uses thereof |
| abstract |
Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of dopamine and/or serotonin in the brain. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11040943-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020079734-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11377421-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10689338-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11713295-B2 |
| priorityDate |
2016-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |